Lilly Says CMS Review Of Beta-Amyloid PET Goes Beyond Medicare Statutory Criteria
This article was originally published in The Pink Sheet Daily
“Improvement in health outcomes” standard would interpret “the statute to require both diagnosis and treatment,” Lilly says about CMS’ recent evaluation of beta-amyloid positron emission tomography in dementia and neurodegenerative disease.
You may also be interested in...
The final coverage decision for Lilly’s Amyvid sticks with the proposal to limit payment to use in clinical trials. That is a setback for Lilly, but reinforces the Medicare agency’s commitment to the Coverage with Evidence Development pathway.
Agency’s final national coverage determination for beta amyloid positron emission tomography to diagnose dementia confirms that Medicare will cover the procedure only in clinical trials. On the positive side, it may offer a bit more flexibility in trial design.
Agency’s final national coverage determination for beta amyloid positron emission tomography in diagnosing dementia confirms stance the diagnostic will be covered only in trial setting for Medicare, but may offer a little more flexibility in trial design.